Keyphrases
Scandinavian
100%
Relapsing-remitting multiple Sclerosis
100%
Prevalence Study
100%
Incidence Studies
100%
Denmark
100%
Injection Site Reaction
100%
Non-interventional Study
100%
Neuromyelitis Optica Spectrum Disorder (NMOSD)
100%
Interferon beta-1a
100%
International Panel
100%
Diagnostic Criteria
100%
Confidence Interval
80%
Multiple Sclerosis Treatment
66%
Disease-modifying Therapy
66%
Treatment Adherence
66%
Treatment Satisfaction
66%
Neuromyelitis Optica
60%
Influenza-like Illness
33%
Technical Problems
33%
Non-interventional
33%
Multiple Sclerosis Diagnosis
33%
Patient Adherence
33%
Incidence Prevalence
20%
Neurology Department
20%
Caucasian Population
20%
Antibody Test
20%
Prevalence Distribution
20%
Geographical Distribution
20%
Population-based Incidence
20%
Multiple Sclerosis
20%
Aquaporin-4 (AQP4)
20%
Geographic Clustering
20%
Danish National Patient Registry
20%
Population-based Study
20%
National Cohort Study
20%
Expert Panel
20%
Medicine and Dentistry
Multiple Sclerosis
100%
Beta1a Interferon
100%
Neuromyelitis Optica
100%
Injection Site Reaction
60%
Patient Compliance
60%
Diseases
40%
Flu Like Syndrome
20%
Side Effect
20%
Arm
20%
Aquaporin 4 Antibody
20%
Pharmacology, Toxicology and Pharmaceutical Science
Beta1a Interferon
100%
Multiple Sclerosis
100%
Myelooptic Neuropathy
100%
Injection Site Reaction
60%
Diseases
40%
Phase IV
20%
Side Effect
20%
Flu Like Syndrome
20%
Aquaporin 4 Antibody
20%